About Us

The Bosch Health Campus draws together all of the Robert Bosch Stiftung’s institutions and activities in the field of health care. Here, more than 3,000 employees work together under one roof in medical and nursing care, in quality and project management, in research, as IT specialists, and as teaching staff.  

The Bosch Health Campus cooperates with a broad number of university, corporate, and civil society partners and plays an active role in networks at home and abroad. As part of the nonprofit Robert Bosch Stiftung, the Bosch Health Campus shares its roots with the Bosch company, which is active across the globe. As such, it is able to draw on the company’s technological expertise where needed, such as for molecular diagnostics and artificial intelligence.

Prof. Dr. Mark Dominik Alscher


Mark Dominik Alscher

Mark Dominik Alscher has around 30 years of experience in health care, serving as a paramedic, physician, chief physician, and medical director. Since 2016, Alscher has been Executive Medical Director of the Robert Bosch Hospital. Together with the Campus’s employees, his goal is to transform the Bosch Health Campus into a hub for patient-centered, cutting-edge medicine with a reputation that extends far beyond Stuttgart and the local region.

International Advisory Board

Convened by the Robert Bosch Stiftung, the International Advisory Board (IAB) advises on the Foundation’s management. The Board supports the Campus in developing strategies and implementing them in fields such as clinical care and treatment, translational research, value-based medicine, and intersectoral care systems. The experts also manage the strategic priorities of the Bosch Health Campus (tumor-related and cardiovascular conditions) and facilitate collaboration with other national and international institutions.


Current members of the International Advisory Board of the Bosch Health Campus


Erwin Böttinger

CEO of the Wyss Center for Bio- and Neuroengineering; Professor of Medicine, Pharmacology and Systems Therapeutics at the Icahn School of Medicine, Mount Sinai, New York, USA


Joel Dudley

Chief Scientific Officer at Tempus (medical technology), Chicago, USA; Professor of Genetics and Genomic Sciences; founding Director at the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai, New York, USA


Heyo Kroemer

Chief Executive Officer of Charité, Universitätsmedizin Berlin; Professor of Pharmacology, Personalized Medicine, Toxicology, and Clinical Pharmacy


Sir David Lane

Professor of Molecular Oncology; Immunologist and Cancer Researcher; Head of Research at the Agency for Science, Technology and Research (A*STAR) in Singapore; Professor of Tumor Suppressor Biology at the Karolinska Institute, Copenhagen


Jacqueline Suzanne Martin

CEO of the Careum School of Health, Zurich, Switzerland; Professor of nursing sciences at the Kalaidos University of Applied Sciences Switzerland


Sir Munir Pirmohamed

David Weatherall Chair of Medicine at the University of Liverpool, UK, and National Health Service (NHS) Chair of Pharmacogenetics; Professor of Molecular and Clinical Pharmacology; Director of the MRC Centre for Drug Safety and the Wolfson Centre for Personalized Medicine in Liverpool, United Kingdom


Simon Tavaré

Professor of Cancer Research and Applied Mathematics; founding Director of the Herbert and Florence Irving Institute  of Cancer Dynamics at Columbia University, New York, USA